PIL on Tuesday 9th January
|When:||Tu 09-01-2018 12:00 - 13:00|
Mendelian randomization (MR) studies use natural randomly allocated variation in gene sequences associated with exposures of biomedical interest to explore their causal relationship to disease. Traditionally, MR studies have focussed on the causal effect of a biomarker for a disease of interest by utilizing multiple variants from across the genome, termed MR for biomarker validation.
Biomarkers of biomedical interest include mRNA expression level, protein or metabolite concentration, and physiological variables such as blood pressure. Among these, proteins are exposures of particular interest because they comprise the targets of most drug treatments. Since proteins are encoded by specific genes, variants within those genes (acting in cis) enable a specific category of MR analysis aimed at drug target validation.
In my lecture I will argue that both types of MR analyses can complement the current drug development via early phase incorporation of human subject based evidence.